On September 30, 2015, the U.S. Food and Drug Administration (FDA) approved a supplemental efficacy application for Opdivo (nivolumab). This approval, identified as BLA 125554 S-2, was granted to the sponsor, Bristol Myers Squibb, and represents an update to the drug's demonstrated effectiveness.
Background
Nivolumab, known commercially as Opdivo, is a widely recognized therapeutic agent. The FDA's approval of a supplemental application for efficacy is considered a major event in the drug's regulatory history. Such approvals typically build upon an initial market authorization, providing new or updated information regarding the drug's effectiveness, which can encompass new patient populations, additional indications, or refined dosing regimens. This particular approval focused specifically on the efficacy profile of nivolumab.
What this means
This supplemental efficacy approval for Opdivo (nivolumab) indicates that the FDA has reviewed and accepted new data supporting the drug's effectiveness. For clinicians, this means there is updated official guidance or an expanded scope for prescribing nivolumab, based on new clinical evidence. While the specific details of the updated efficacy are not provided in this summary, supplemental approvals are crucial for refining treatment strategies and expanding therapeutic options. Researchers and patient advocates would consult the full FDA approval document to understand the precise implications for patient care and future studies.
Source
The information regarding this supplemental approval was sourced directly from the U.S. Food and Drug Administration's official database. The record, identified by BLA 125554 S-2, pertains to the approval of a supplemental application for Opdivo (nivolumab) on September 30, 2015, and is publicly available on accessdata.fda.gov.